{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:02:31Z","timestamp":1790661751770,"version":"4.1.0"},"reference-count":10,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T00:00:00Z","timestamp":1523923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,7,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Treatment with anti-programmed cell death protein 1 (PD-1) antibodies has demonstrated clinical efficacy in a whole range of malignancies including advanced melanoma, renal cell cancer, bladder cancer, and non-small cell lung cancer. Immune-related adverse events are a unique side effect of checkpoint regulator therapy including anti-PD-1 antibodies. Treatment-related autoimmunity can occur in any organ system, with the median onset usually within 5\u201315 weeks from the commencement of therapy, depending on the organ system involved. This study describes for the first time a case of delayed autoimmunity occurring 8 months after discontinuing treatment with the anti-PD-1 antibody nivolumab in a patient with metastatic melanoma. The case highlights the need for ongoing surveillance of patients treated with immune checkpoint inhibitors even after cessation of therapy, especially as patients increasingly stop treatment after achieving durable responses.<\/jats:p>","DOI":"10.1634\/theoncologist.2017-0531","type":"journal-article","created":{"date-parts":[[2018,4,17]],"date-time":"2018-04-17T18:50:24Z","timestamp":1523991024000},"page":"849-851","source":"Crossref","is-referenced-by-count":51,"title":["Delayed Autoimmune Toxicity Occurring Several Months After Cessation of Anti-PD-1 Therapy"],"prefix":"10.1093","volume":"23","author":[{"given":"Sagun","family":"Parakh","sequence":"first","affiliation":[{"name":"Medical Oncology Unit, Austin Health, Melbourne, Victoria, Australia"},{"name":"Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia"},{"name":"La Trobe University School of Cancer Medicine, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Cebon","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Austin Health, Melbourne, Victoria, Australia"},{"name":"Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia"},{"name":"La Trobe University School of Cancer Medicine, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Klein","sequence":"additional","affiliation":[{"name":"Medical Oncology Unit, Austin Health, Melbourne, Victoria, Australia"},{"name":"Olivia Newton-John Cancer Research Institute, Melbourne, Victoria, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,4,17]]},"reference":[{"key":"2021122511044427300_onco12432-bib-0001","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.immuni.2016.04.023","article-title":"Targeting T cell co-receptors for cancer therapy","volume":"44","author":"Callahan","year":"2016","journal-title":"Immunity"},{"key":"2021122511044427300_onco12432-bib-0002","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","article-title":"Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies","volume":"26","author":"Naidoo","year":"2015","journal-title":"Ann Oncol"},{"key":"2021122511044427300_onco12432-bib-0003","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1200\/JCO.2015.66.1389","article-title":"Safety profile of nivolumab monotherapy: A pooled analysis of patients with advanced melanoma","volume":"35","author":"Weber","year":"2016","journal-title":"J Clin Oncol"},{"key":"2021122511044427300_onco12432-bib-0004","author":"Larkin","year":"2017"},{"key":"2021122511044427300_onco12432-bib-0005","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(17)31601-X","article-title":"Pembrolizumab versus ipilimumab for advanced melanoma: Final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)","volume":"390","author":"Schachter","year":"2017","journal-title":"Lancet"},{"key":"2021122511044427300_onco12432-bib-0006","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1001\/jama.2016.4059","article-title":"Association of pembrolizumab with tumor response and survival among patients with advanced melanoma","volume":"315","author":"Ribas","year":"2016","journal-title":"JAMA"},{"key":"2021122511044427300_onco12432-bib-0007","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","article-title":"Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy","volume":"60","author":"Hofmann","year":"2016","journal-title":"Eur J Cancer"},{"key":"2021122511044427300_onco12432-bib-0008","doi-asserted-by":"crossref","first-page":"3167","DOI":"10.1200\/JCO.2009.26.7609","article-title":"Phase I study of single-agent anti\u2013programmed death-1 (MDX-1106) in refractory solid tumors: Safety, clinical activity, pharmacodynamics, and immunologic correlates","volume":"28","author":"Brahmer","year":"2010","journal-title":"J Clin Oncol"},{"key":"2021122511044427300_onco12432-bib-0009","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1097\/CMR.0000000000000336","article-title":"The cessation of anti-PD-1 antibodies of complete responders in metastatic melanoma","volume":"27","author":"Ladwa","year":"2017","journal-title":"Melanoma Res"},{"key":"2021122511044427300_onco12432-bib-0010","article-title":"Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma","author":"Robert","year":"2017","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1634\/theoncologist.2017-0531","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1634\/theoncologist.2017-0531","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/7\/849\/41915162\/oncolo_23_7_849.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/23\/7\/849\/41915162\/oncolo_23_7_849.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,25]],"date-time":"2021-12-25T11:05:33Z","timestamp":1640430333000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/23\/7\/849\/6439615"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,17]]},"references-count":10,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2018,4,17]]},"published-print":{"date-parts":[[2018,7,1]]}},"URL":"https:\/\/doi.org\/10.1634\/theoncologist.2017-0531","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,7,1]]},"published":{"date-parts":[[2018,4,17]]}}}